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Geoffrey R HillThe procedural requirements of bonemarrow transplantation (BMT) predispose to the dramatic induction of
local and systemic inflammatory states and can be conceived in relation to transplant conditioning, the acti-
vation of alloreactive T cells and finally, the effector stage of graft-versus-host disease (GVHD). It is now clear
that alloreactive T cell responses result in a dramatic and often fulminant amplification of systemic inflamma-
tion that is responsible for many of the characteristic causes of transplant-related mortality. The pathways by
which inflammatory cytokines are induced after BMTand the resultant pathologies will be discussed.
Biol Blood Marrow Transplant 15: 139-141 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Inflammation, Cytokine, Graft-versus-host disease, T cell, Antigen-presenting cellThis report explores the role of inflammation in the
complications of bonemarrow transplantation (BMT).
The procedural requirements of BMT predispose to
the dramatic induction of local and systemic
inflammatory states and can be conceived in relation
to transplantation conditioning, activation and expan-
sion of alloreactive T cells, and the final effector stage
of graft-versus-host disease (GVHD). Additive allor-
eactive T cell effects lead to the dramatic and often
fulminant inflammatory states characteristic of alloge-
neic BMT. For the purpose of this discussion, the
action of pathogenic proinflammatory cytokines (eg,
tumor necrosis factor [TNF], interleukin [IL]-1, inter-
feron [IFN]-g) induced at transplantation is considered




The vast majority of transplantation candidates are
heavily pretreated with chemoradiotherapy into a state
of relative minimal residual disease (ie, remission). The
impact of this on the induction of subsequent inflamma-
tion has not been well studied, but there are indications
that this has an influence on transplantation outcome. It
is logical (although not yet experimentally validated)Bone Marrow Transplantation Laboratory, Queensland
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tially toxic effects of transplantation conditioning by
previous therapy, which will predispose to increased
inflammation in these patients. Studies demonstrating
enhanced induction of TNF in patients with advanced
disease undergoing transplantation [1] are consistent
with this. Conversely, at the time of transplantation,
such recipients may be relatively depleted of important
cellular populations (eg, tissue macrophages, B cells)
[2,3] that contribute to inflammation during transplan-
tation and thusmaybeat increased risk for inflammatory
cytokine generation during conditioning. Experimental
data demonstrating lower inflammatory cytokine levels
after transplantation in recipients pretreated with
chemotherapy [2] and the enhanced inflammatory cyto-
kine levels seen in chemotherapy-naı¨ve patients
undergoing transplantation for chronic myelogenous
leukemia support this concept [4,5]. Thus, the effects
of previous therapy on both hematopoietic and nonhe-
matopoietic tissue likely will influence the generation
of inflammation during subsequent transplantation.CONDITIONING-INDUCED INFLAMMATION
The initiation of acute GVHD depends the pres-
ence of naı¨veT cells within the donor graft and their in-
teraction with allodisparate antigen-presenting cells
(APCs) [6,7]. This process is intimately influenced by
the BMT conditioning process and its ability to modu-
late this process by:
1) Depletion of host APC
2) Activation of residual host APC
3) Damage to gastrointestinal luminal integrity,
allowing escape of toll receptor ligands into the
systemic circulation (e.g. LPS, CpG).
Thus, the type (ie, total body irradiation [TBI] or
chemically based) [8] and intensity (eg, myeloablative139
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differential states of inflammation after allogeneic
BMT. This effect is heavily influenced by the ability
of these conditioning protocols to maintain differen-
tial numbers of activated APCs at the time of trans-
plantation, thereby dictating the efficiency of the
donor T cell–host APC encounter). Thus, the hyper-
acute inflammatory states induced after TBI-based
conditioning is the result of donor T cells encounter-
ing small numbers of highly activated allodisparate
host APC. In contrast, the later-onset acute inflamma-
tory state occurring after nonablative allogeneic BMT
likely is the result of donor T cells interacting with
large numbers of less activated host APCs surviving
for prolonged periods.
The propensity of acute GVHD for target organs
with an environmental interface and thus direct patho-
gen exposure (eg skin,GI tract, and lung)may not be co-
incidental. TBI is known to promote inflammatory
cytokine generation from macrophages in response to
TLR ligands [9], and sensitivity to LPS is enhanced
markedly in GVHD, resulting in enormous inflamma-
tory cytokine generation relative to most other disease
states. This effect depends in large part on the priming
effect of IFN-g generation from alloreactive donor T
cells [10]. A large body of evidence indicates that TBI
promotes the release ofTLR ligands frombacterial flora
within the GI tract into the systemic circulation [11].
Significant ongoing efforts have been aimed at limiting
mucosal damage during conditioning by providing pro-
tective cytokines (especially KGF, [11]) or reducing the
dose intensity of preparative chemoradiotherapy.ALLOREACTIVE T CELL RESPONSES
The intensity of the inflammatory response after
transplantation is dictated in large part by the presence
or absence of allodisparate T cells and the dramatic am-
plification of this response in the former setting. Indeed,
the activation of donor T cells by host APCs character-
istically results inTh1 differentiation and the generation
of large amounts of IFN-g. IFN-g promotes the matu-
ration (eg,CD40expression)ofAPCsand thegeneration
of IL-12 secretion, serving as a positive feedback loop to
further promoteTh1 differentiation and the secretion of
large amounts of cytokine into the systemic circulation
[12]. Although TNF also is produced in large amounts
by donor T cells and plays an important role in the in-
duction of acute GVHD [13,14], experimental evidence
confirms thatmononuclear cell andmacrophagepopula-
tions also are important sources of this cytokine and are
generated in response to TLR ligation [15]. In addition,
TNF can serve as an autocrine growth factor for the in-
duction of alloreactive T cell expansion [16]. The Th2
cytokines generally are associated with delayed, less se-
vere acute GVHD, although these cytokines contributeto the overall spectrum of disease [17,18]. The role of
Th17 differentiation in GVHD remains largely un-
known and will be defined more clearly over the next
few years.INFLAMMATORY EFFECTORS OF ACUTE
GVHD
The role of inflammatory cytokines as the second
component of a dual-pronged attack on target tissues
(in association with cellular cytolytic pathways) was
established by Teshima et al. [19]. This study confirmed
the ability togenerate inflammatorycytokine–dependent
GVHDtarget organ damage independent ofmajor his-
tocompatibility complex (MHC) expression on host
target tissue. This effect was present in both CD4-
and CD8-dependent GVHD, although it was most
dominant in the former setting. Of the inflammatory
cytokines, TNF is known to be a dominant mediator
of pathology, particularly within the GI tract [11],
and the neutralization of this cytokine shows particular
promise in the treatment of acute GVHD [20]. The
role of IL-1 in acute GVHD remains well established
in experimental models from numerous groups, al-
though the importance in clinical acute GVHD is less
clear, considering the failure of a soluble antagonist
to demonstrate any benefit in a randomized clinical
trial [21].
The effect of donor T cell–derived IFN-g as an
effector molecule in acute GVHD is complex, because
this cytokine has organ-specific effects whereby it is
directly pathogenic to the GI tract but prevents the
induction of lung GVHD (idiopathic pneumonia syn-
drome) [22]. In addition, this cytokine appears to be
responsible for much of the bone marrow suppression
occurring during GVHD [23].INFLAMMATORY RESPONSES IN CHRONIC
GVHD
The pathogenesis of chronic GVHD remains less
well established, although both experimentally and
clinically, it appears that autoantibodies and B cells
contribute to the process through the stimulation of fi-
brosis [24]. The latter process is transforming growth
factor (TGF)-g dependent, and neutralization of
TGF-g appears to be efficacious in experimental
models [3], as does clinical B cell depletion with mono-
clonal antibodies [25]. Thus, although inflammation
may contribute to thymic atrophy and the emergence
of autoreactive T cells after transplantation, chronic
GVHD itself does not appear to be characterized by
a significant proinflammatory state.
The recognition of the central role of inflamma-
tion as a pathogenic, MHC-indiscriminate effector
pathway of host damage represents an important
Biol Blood Marrow Transplant 15:139-141, 2009 141Inflammation and Bone Marrow Transplantationadvance in our understanding of the complications of
BMT and has opened the door for new therapies to
block these soluble effectors of disease.ACKNOWLEDGMENTS
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